

**FOR IMMEDIATE RELEASE**  
**May 30, 2007**

**For more information, contact:**  
**Michael Levin-Epstein, Editor-in-Chief**  
**(202) 222-0897; mdl@fdli.org**

**FOOD AND DRUG LAW INSTITUTE SPONSORS NATIONAL COLLOQUIUM  
ON RIGHTS, RESPONSIBILITIES AND OTHER ISSUES RELATED TO THE  
PROVISION OF UNAPPROVED DRUGS**

*Groundbreaking Forum June 28, 2007 — From Abigail to Penelope: Individual to Corporate Rights — Addresses Pharmaceutical Industry, FDA, Venture Capital Positions on Experimental Drugs for Terminally Ill Patients*

Do pharmaceutical manufacturers have any responsibility to provide experimental drugs to terminally ill patients, even when all risks are assumed? What issues and concerns are most prominent factors in making access requests and decisions?

Those are some of the critical questions a panel of experts will discuss and debate at a landmark Colloquium — *From Abigail to Penelope: Individual to Corporate Rights* — sponsored by the Food and Drug Law Institute (FDLI), June 28, 2007, at the Fulbright Center, Hogan & Hartson, in Washington, DC.

This meeting is the second in a series of colloquia sponsored by FDLI. The sold-out first Colloquium, *Whose Life Is It, Anyway?*, addressed the key question in *Abigail Alliance for Better Access to Developmental Drugs v. von Eschenbach*: Should terminally ill patients be allowed access to drugs not approved by FDA? The U.S. Court of Appeals for the District of Columbia is expected to issue a ruling in the case in the next few months.

This Colloquium focuses on the situation presented by a young girl, Penelope, profiled on the front page of *The Wall St. Journal* of May 1: Fighting for her life, Penelope seeks access to an unapproved drug. FDA has no objections, but the pharmaceutical manufacturer and its venture capitalist backer decline to provide the drug despite pleas by family, influential friends and politicians. .

The Colloquium will include interactive audience and panel discussions on several important aspects of this dilemma, including industry and governmental responsibility, ethical considerations and tort reform.

The panel of experts includes:

- \* **Janet Woodcock, MD**, Deputy Commissioner and Chief Medical Officer, Food and Drug Administration;
- \* **Scott Ballenger**, Partner, Latham & Watkins;
- \* **Scott Gottlieb, MD**, Resident Fellow, American Enterprise Institute; and

\* **Jonathan D. Moreno**, David and Lyn Silfen University Professor at the University of Pennsylvania and Senior Fellow, Center for American Progress.

Registration is \$295 for FDLI members and \$395 for non-members. Attendance is limited to the first 75 paid registrants.

To register, visit <http://fdli.org> or call (800) 956-6923 or (202) 371-1420.

*Media:* To register, or to find out more about the Colloquium, contact Michael Levin-Epstein, Editor-in-Chief, FDLI, (202) 222-0897; mdl@fdli.org.

---

Founded in 1949, FDLI publishes the award-winning, peer-reviewed *Food and Drug Law Journal*; the bimonthly magazine *Update*; *FDA Directory*; and dozens of books and publications for attorneys, regulatory affairs practitioners, scientists, health care professionals, government employees and marketers in the food and drug field.